루닛

328130KOSDAQ소프트웨어 개발 및 공급업

39.6 / 100

Reference Date: 2026-07-24

Financial Score7.5 / 40

News Sentiment19.1 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE is below the industry average, PBR raises overvaluation concerns. Declined 11.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Lunit is a deep learning-based medical AI company specializing in cancer diagnosis and breast cancer screening solutions, leveraging AI-assisted detection and imaging biomarker technologies. Its core products, Lunit INSIGHT and Lunit SCOPE, drive innovation in the medical AI market, with 92% of revenue generated from overseas markets, including the U.S. and Japan.

Number of Employees

272people

Average Salary

93.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 12.284.0Point

PBR

5.33Industry Average 0.890.0Point

6.0x industry avg (risky)

ROE

-31.58Industry Average 1.100.0Point

Well below industry avg

Debt Ratio

14.75Industry Average 7.930.5Point

1.9x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲84.7% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼41.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -32.3% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 3Neutral 1Negative 0Average Sentiment Score 76.2

Positive
진료지 쓰고 병원 이송 돕고…AI로 필수의료 공백 메운다
정부의 AI 기반 의료 전략 도입으로 루닛의 필수의료 서비스 확장 가능성이 높아져 긍정적 영향 예상.
Positive
루닛, 글로벌 AI 컨소시엄 합류…신약 개발 속도 높인다
루닛이 글로벌 신약개발 AI 컨소시엄에 참여함으로써 기술 협력 강화와 혁신적인 신약 개발 가속화 기대.
Positive
루닛, 글로벌 신약개발 AI 연합군 합류…정밀의료 영토 확장
루닛이 글로벌 신약개발 AI 컨소시엄에 참여함으로써 정밀의료 분야에서의 영향력 확대가 기대된다.

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 9,840Won52-week high 45,92852-week low 9,200

1-month return1.0Point

1m -11.67% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-06-30